Sign Out
Hypersensitivity to capecitabine or fluorouracil or any component of formulation.
In patients with severe renal impairment (creatinine clearance below 30 ml/min).
In patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.
Treatment with folic acid may affect the metabolism of capecitabine.
In patients with severe hepatic impairment.
In patients with severe neutropenia.
Continue with Google